ESPE Abstracts

Introduction: The goal of treating short children with growth hormone (GH) is to normalize adult height adjusted for mid parental height (MPH). We obtained adult height data on 87 patients (23 girls, 64 boys) treated with GH who originally participated in a randomized, prospective, open-label clinical trial with either personalized dose based on a prediction model (n=58), or standard dose (n=29). The children were either growth hormone deficient (GHD) according to both stimulation test and spontaneous secretion (33%), or had idiopathic short stature (ISS).

Aim: To evaluate height outcome in GH treated patients with personalized approach, and find possible gender differences.

Methods: The different dose regimes were compared for mean GH dose and difference between MPH and adult height. The patients were then divided in two groups according to gender. The gender divided groups were compared for mean (SD); IGF-1, delta IGF-1 and GH dose from start until end of treatment, age at GH start, difference between MPH and adult height. Percentage of GHD diagnosis were also compared. Mann Whitney U test and Qi Square test were applied. P-values <0.05 were considered statistical significant.

Results: No mean (SD) differences were found for the personalized dose group vs standard dose group:

Mean (SD) for girls and boys:

26 (40%) of the boys and 15 (65%) of the girls had an adult height within 0.5 SDS from MPH. 25% of the males grew better than 0.5SDS from MPH while none of the girls did.

Conclusion:• No differences in mean dose nor in adult height outcome were found between the groups treated with personalized approach or standard dose.

• Although the mean GH dose did not differ between the gender groups, girls resulted in an adult height further beneath MPH than the boys. An older age at GH start and lower delta IGF-1 during treatment could be the explanation for the findings.